News | March 16, 2012

Cell>Point, FDA Agree on Phase 3 Trial of Technetium-99m Lung Cancer Imaging Agent

March 15, 2012 - Cell>Point announced that it has received a letter from the U.S. Food and Drug Administration (FDA) indicating agreement on a Special Protocol Assessment (SPA) for Cell>Point’s Phase 3 pivotal clinical study of technetium-99m-EC-G in lung cancer.

The Phase 3 study will assess use of Cell>Point’s molecular imaging product candidate, technetium-99m-EC-G (EthylenediCysteine-n-acetyl-Glucosamine), in the diagnosis and staging of lung cancer.

Study patients receive technetium-99m-EC-G (99mTc-EC-G) intravenously, and a picture, or image, of the cancer area is taken using a Single Photon Emission Computed Tomography (SPECT) camera, commonly referred to as a gamma camera.

“We are extremely pleased to receive agreement from the FDA for this Special Protocol Assessment since it provides us confidence that our study design and statistical analysis plan have the potential to provide results that lead to product approval,” said David Rollo, M.D., Ph.D., president of Cell>Point.

Patients in the study will receive a SPECT scan with 99mTc-EC-G, and a PET scan (Positron Emission Tomography) with fluorine-18 FluoroDeoxyGlucose (18F-FDG). Results will then be independently evaluated, scored and compared for accuracy in diagnosing the presence and location of primary as well as metastatic lesions.

About Special Protocol Assessments

A Special Protocol Assessment is a binding declaration between the trial sponsor and the FDA indicating that the Phase 3 clinical study design, endpoints and statistical analyses are acceptable to support regulatory approval of the product. Final marketing approval depends on study results and an evaluation of benefit/risk profile.

About Technetium-99m-EC-G

Technetium-99m-EC-G is a cancer and cardiovascular diagnostic imaging agent developed for use with SPECT cameras, which are widely available throughout the world. In cancer, Phase 2 clinical trial results showed 100 percent concordance between 99mTc-EC-G and 18F-FDG in non-small cell lung cancer lesion

location, size and confidence that lesions represented cancer. For cardiology, Cell>Point is preparing to start a Phase 2 clinical study to evaluate technetium-99m-EC-G in diagnosing patients with Coronary Artery Disease (CAD). One of the Phase 2 objectives is to compare results of giving technetium-99m-EC-G to patients “at rest” to results of a traditional Myocardial Perfusion Imaging (MPI) “stress and rest” study. (The EC-G rest-only study takes 30 to 45 minutes, whereas a traditional MPI study takes 5 to 7 hours.) Results from the Phase 1b CAD study were very encouraging.

For Technetium-99m-EC-G, the company has completed a Brazil license and a select-country Asia Pacific license.

For more information: www.cellpointweb.com

Related Content

Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...